Tue, 11 August 2020
Supreme Council For Health (SCH) President, Head of the National Taskforce for Combating COVID-19, Lieutenant-General Dr. Shaikh Mohammed bin Abdulla Al-Khalifa has today initiated phase III clinical trial for a COVID-19 inactivated vaccine which will be tested on an estimated 6000 citizens and resident volunteers across the Kingdom of Bahrain.
He paid a visit to the COVID-19 Clinical Trials Centre at the Bahrain International Exhibition and Convention Centre (BIECC) and inspected the readiness of the facility to accommodate the volunteers who will be subjected to the test for one year.
During the visit, he was briefed about medical equipment, inspected the hall for collecting samples from volunteers and met doctors who are incharge of the study in the Kingdom of Bahrain.
The study will be carried in collaboration with the United Arab Emirates (UAE) G42 Healthcare, an artificial intelligence company based Abu Dhabi, the UAE.
The phase III clinical trials will be conducted using a a COVID-19 inactivated vaccine developed by Sinopharm CNBG the world’s sixth largest producer of vaccines in the world.
Dr. Shaikh Mohammed bin Abdulla Al-Khalifa hailed strong cooperation with health authorities in the UAE and the China National Biotec Group, a subsidiary of the Sinopharm CNBG as well as G42 Healthcare.